Treatment of chorea
treatment of chorea pharmacological management
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 12373
Huntington disease chorea Sydenham chorea therapy
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 12373
| Drug | Mechanism | Notes |
|---|---|---|
| Tetrabenazine | Presynaptic dopamine depletion (VMAT2 inhibitor) | FDA-approved for HD chorea; risk of secondary parkinsonism, depression, sedation |
| Deutetrabenazine (Austedo) | VMAT2 inhibitor (deuterated form) | FDA-approved; longer half-life, better tolerability than tetrabenazine |
| Valbenazine | VMAT2 inhibitor | Approved for tardive dyskinesia; used off-label for HD chorea |
| Haloperidol / Fluphenazine | D2 receptor blockers | Effective for chorea; risk of tardive dyskinesia with long-term use |
| Olanzapine / Risperidone | Atypical antipsychotics | Dopamine-blocking; may control chorea with lower tardive dyskinesia risk |
| Amantadine | NMDA antagonist | Modest anti-choreic effect in some patients |
| Cause | Treatment |
|---|---|
| Thyrotoxicosis | Antithyroid therapy (chorea resolves with euthyroidism) |
| Polycythemia vera | Treat underlying disorder; low-dose aspirin |
| Hyperglycemic chorea (non-ketotic hyperosmolar) | Correct hyperglycemia; chorea typically resolves |
| SLE/antiphospholipid syndrome | Immunosuppression (steroids, hydroxychloroquine), anticoagulation |
| Wilson's disease | Penicillamine or trientine (copper chelation); zinc supplementation |